Nason, Rebecca
Büll, Christian
Konstantinidi, Andriana
Sun, Lingbo
Ye, Zilu
Halim, Adnan
Du, Wenjuan
Sørensen, Daniel M. http://orcid.org/0000-0001-8811-2506
Durbesson, Fabien
Furukawa, Sanae
Mandel, Ulla http://orcid.org/0000-0001-7012-9836
Joshi, Hiren J. http://orcid.org/0000-0002-8192-2829
Dworkin, Leo Alexander http://orcid.org/0000-0001-7185-6680
Hansen, Lars
David, Leonor http://orcid.org/0000-0003-4207-9258
Iverson, Tina M. http://orcid.org/0000-0001-8816-6352
Bensing, Barbara A.
Sullam, Paul M.
Varki, Ajit
Vries, Erik de
de Haan, Cornelis A. M. http://orcid.org/0000-0002-4459-9874
Vincentelli, Renaud
Henrissat, Bernard http://orcid.org/0000-0002-3434-8588
Vakhrushev, Sergey Y. http://orcid.org/0000-0002-0418-5765
Clausen, Henrik http://orcid.org/0000-0002-0915-5055
Narimatsu, Yoshiki http://orcid.org/0000-0003-1428-5695
Funding for this research was provided by:
Danmarks Grundforskningsfond (DNRF107)
Lundbeckfonden
Article History
Received: 22 October 2020
Accepted: 8 June 2021
First Online: 1 July 2021
Competing interests
: The University of Copenhagen has filed a patent application relating to X409 mucin-binding peptides (EPO application EP21177857.6, pending). R.N., C.B., Y.N., B.H., and H.C. are named inventors. GlycoDisplay Aps, Copenhagen, Denmark, has obtained a license to the patent application. Y.N. and H.C. are co-founders of GlycoDisplay Aps and hold ownerships and financial interest in the company. The remaining authors declare no competing interests.